Stock Comparison

JNJ vs NUVB

Johnson & Johnson vs Nuvation Bio Inc

The Verdict

NUVB takes this one.

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Winner

NUVB

Nuvation Bio Inc

8.7

out of 10

Hidden Gem

Head-to-Head

N/A

Market Cap

$1.6B

N/A

P/E Ratio

-7.7

N/A

Profit Margin

-325.3%

N/A

Return on Equity

0.0%

N/A

Debt-to-Equity

0.2

Conservative

Overall Risk

Aggressive

1.0

DVR Score

8.7

The Deep Dive

JNJ1.0/10

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Full JNJ Analysis

NUVB8.7/10

Nuvation Bio (NUVB) sustains its high 10x growth potential, reflecting robust progress in its transformation to a commercial-stage oncology firm. The Q4 2025 revenue beat and initial IBTROZI® product revenue of $24.7M with 216 new patient starts validate its commercial launch. Furthermore, the EMA's validation of taletrectinib's marketing application and upcoming pivotal data presentation at AACR ...

Full NUVB Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.